{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:44:51Z","timestamp":1793897091439,"version":"4.8.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T00:00:00Z","timestamp":1726876800000},"content-version":"am","delay-in-days":295,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jad.2023.09.030","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T15:35:10Z","timestamp":1695224110000},"page":"166-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Early effects predict trajectories of response to esketamine in treatment-resistant depression"],"prefix":"10.1016","volume":"342","author":[{"given":"Isaure","family":"Estrade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-C\u00e9cile","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Sylvestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Danon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Perrain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Vinckier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lila","family":"Mekaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Gaillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Advenier-Iakovlev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella Letizia","family":"Mancusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphn\u00e9e","family":"Poupon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"De Maricourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Gorwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2023.09.030_bb0005","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3389\/fpsyt.2020.00844","article-title":"The antidepressant effect of ketamine is dampened by concomitant benzodiazepine medication","volume":"11","author":"Andrashko","year":"2020","journal-title":"Front. Psych."},{"key":"10.1016\/j.jad.2023.09.030_bb0010","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1476-5381.1983.tb11031.x","article-title":"The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate","volume":"79","author":"Anis","year":"1983","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jad.2023.09.030_bb0015","first-page":"1","article-title":"Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis","author":"Bahji","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jad.2023.09.030_bb0020","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2023.09.030_bb0025","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/1060028019892644","article-title":"Esketamine: a novel option for treatment-resistant depression","volume":"54","author":"Bozymski","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.jad.2023.09.030_bb0030","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/da.23138","article-title":"At baseline patients treated with esketamine have higher burden of disease than other patients with treatment resistant depression: learnings from a population based study","volume":"38","author":"Cepeda","year":"2021","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2023.09.030_bb0035","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jad.2020.09.056","article-title":"Comparative effectiveness of esketamine in the treatment of anhedonia in bipolar and unipolar depression","volume":"278","author":"Delfino","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2023.09.030_bb0040","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2217\/cer-2020-0276","article-title":"Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression","volume":"10","author":"Desai","year":"2021","journal-title":"Journal of Comparative Effectiveness Research"},{"key":"10.1016\/j.jad.2023.09.030_bb0045","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.2147\/NDT.S314874","article-title":"Effect of concomitant benzodiazepine use on efficacy and safety of esketamine nasal spray in patients with major depressive disorder and acute suicidal ideation or behavior: pooled randomized, controlled trials","volume":"17","author":"Diekamp","year":"2021","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jad.2023.09.030_bb0050","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/ijnp\/pyaa034","article-title":"Treatment response of add-on Esketamine nasal spray in resistant major depression in relation to add-on second-generation antipsychotic treatment","volume":"23","author":"Dold","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2023.09.030_bb0055","series-title":"Spravato [WWW Document]","author":"European Medicines Agency (EMA)","year":"2019"},{"key":"10.1016\/j.jad.2023.09.030_bb0060","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1)","volume":"22","author":"Fedgchin","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2023.09.030_bb0065","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4088\/JCP.08m04309","article-title":"A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method","volume":"70","author":"Fekadu","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2023.09.030_bb0070","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12888-018-1679-x","article-title":"Standardisation framework for the Maudsley staging method for treatment resistance in depression","volume":"18","author":"Fekadu","year":"2018","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2023.09.030_bb0075","series-title":"FDA Approves New Nasal Spray Medication for Treatment-Resistant Depression [WWW Document]","author":"Food and Drug Administration (FDA)","year":"2019"},{"key":"10.1016\/j.jad.2023.09.030_bb0080","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/ijnp\/pyz064","article-title":"The CINP guidelines on the definition and evidence-based interventions for treatment-resistant bipolar disorder","volume":"23","author":"Fountoulakis","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2023.09.030_bb0085","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/da.22968","article-title":"Defining treatment-resistant depression","volume":"37","author":"Gaynes","year":"2020","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2023.09.030_bb0090","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2023.09.030_bb0095","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0895-4356(03)00177-X","article-title":"The diagnostic odds ratio: a single indicator of test performance","volume":"56","author":"Glas","year":"2003","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.jad.2023.09.030_bb0100","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/s41386-020-00935-x","article-title":"Distinct trajectories of response to prefrontal tDCS in major depression: results from a 3-arm randomized controlled trial","volume":"46","author":"Goerigk","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2023.09.030_bb0105","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1001\/archgenpsychiatry.2011.132","article-title":"Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses","volume":"68","author":"Gueorguieva","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2023.09.030_bb0110","doi-asserted-by":"crossref","first-page":"12022","DOI":"10.3390\/ijerph182212022","article-title":"Anxiety, depression and quality of life\u2014a systematic review of evidence from longitudinal observational studies","volume":"18","author":"Hohls","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.jad.2023.09.030_bb0115","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1017\/S0033291720003633","article-title":"Why we need more research into the placebo response in psychiatry","volume":"50","author":"Huneke","year":"2020","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2023.09.030_bb0120","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s12888-019-2222-4","article-title":"The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study","volume":"19","author":"Jaffe","year":"2019","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2023.09.030_bb0125","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/da.22832","article-title":"Response rate profiles for major depressive disorder: characterizing early response and longitudinal nonresponse","volume":"35","author":"Kelley","year":"2018","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2023.09.030_bb0130","first-page":"198","article-title":"Assessment Scales in Depression, Mania and Anxiety","author":"Lam","year":"2005","journal-title":"London: Taylor & Francis"},{"key":"10.1016\/j.jad.2023.09.030_bb0135","first-page":"8","article-title":"Patient response trajectories in major depressive disorder","volume":"50","author":"Larsen","year":"2020","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.jad.2023.09.030_bb0140","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020683","article-title":"Framework to construct and interpret latent class trajectory modelling","volume":"8","author":"Lennon","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.jad.2023.09.030_bb0145","doi-asserted-by":"crossref","first-page":"110126","DOI":"10.1016\/j.pnpbp.2020.110126","article-title":"Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: results from the Canadian Rapid Treatment Center of Excellence","volume":"105","author":"Lipsitz","year":"2021","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2023.09.030_bb0150","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jad.2011.12.021","article-title":"Do sub-syndromal manic symptoms influence outcome in treatment resistant depression in adolescents? A latent class analysis from the TORDIA study","volume":"138","author":"Maalouf","year":"2012","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2023.09.030_bb0155","doi-asserted-by":"crossref","DOI":"10.1111\/bdi.13296","article-title":"Treating bipolar depression with esketamine: safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression","author":"Martinotti","year":"2023","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2023.09.030_bb0160","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1017\/S0033291714001603","article-title":"A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes","volume":"45","author":"McGirr","year":"2015","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2023.09.030_bb0165","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.09.030_bb0170","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1600-0447.1985.tb08073.x","article-title":"Profiles of antidepressant activity with the Montgomery-Asberg Depression Rating Scale","volume":"320","author":"Montgomery","year":"1985","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.jad.2023.09.030_bb0175","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1146\/annurev.clinpsy.121208.131413","article-title":"Group-based trajectory modeling in clinical research","volume":"6","author":"Nagin","year":"2010","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"10.1016\/j.jad.2023.09.030_bb0180","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19r12889","article-title":"Efficacy of esketamine augmentation in major depressive disorder: a meta-analysis","volume":"81","author":"Papakostas","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jad.2023.09.030_bb0185","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.09.030_bb0190","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/bmsp.12000","article-title":"Analysis of multivariate mixed longitudinal data: a flexible latent process approach","volume":"66","author":"Proust-Lima","year":"2013","journal-title":"Br. J. Math. Stat. Psychol."},{"key":"10.1016\/j.jad.2023.09.030_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v078.i02","article-title":"Estimation of extended mixed models using latent classes and latent processes: the R package lcmm","volume":"78","author":"Proust-Lima","year":"2017","journal-title":"Journal of Statistical Software"},{"key":"10.1016\/j.jad.2023.09.030_bb0200","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jagp.2014.05.002","article-title":"Older age is associated with rapid remission of depression after electroconvulsive therapy: a latent class growth analysis","volume":"23","author":"Rhebergen","year":"2015","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.jad.2023.09.030_bb0205","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1192\/bjp.2018.27","article-title":"Depression and hopelessness as risk factors for suicide ideation, attempts and death: meta-analysis of longitudinal studies","volume":"212","author":"Ribeiro","year":"2018","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.09.030_bb0210","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1146\/annurev-clinpsy-072120-014126","article-title":"Ketamine and the future of rapid-acting antidepressants","volume":"17","author":"Riggs","year":"2021","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"10.1016\/j.jad.2023.09.030_bb0215","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s41687-022-00453-y","article-title":"Assessing the meaningful change threshold of Quality of Life in Depression Scale using data from two phase 3 studies of esketamine nasal spray","volume":"6","author":"Rozjabek","year":"2022","journal-title":"Journal of Patient-Reported Outcomes"},{"key":"10.1016\/j.jad.2023.09.030_bb0220","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"AJP"},{"key":"10.1016\/j.jad.2023.09.030_bb0225","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/10705511.2016.1247646","article-title":"The GRoLTS-Checklist: guidelines for reporting on latent trajectory studies","volume":"24","author":"van de Schoot","year":"2017","journal-title":"Struct. Equ. Model. Multidiscip. J."},{"key":"10.1016\/j.jad.2023.09.030_bb0230","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jad.2009.10.007","article-title":"Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression","volume":"121","author":"Suppes","year":"2010","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2023.09.030_bb0235","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s40261-022-01193-z","article-title":"Efficacy and safety of subcutaneous esketamine in the treatment of suicidality in major depressive disorder and bipolar depression","volume":"42","author":"Surjan","year":"2022","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.jad.2023.09.030_bb0240","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/14737175.2019.1640604","article-title":"Esketamine for treatment resistant depression","volume":"19","author":"Swainson","year":"2019","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.jad.2023.09.030_bb0245","series-title":"StatPearls","article-title":"Odds ratio","author":"Tenny","year":"2022"},{"key":"10.1016\/j.jad.2023.09.030_bb0250","doi-asserted-by":"crossref","first-page":"115165","DOI":"10.1016\/j.psychres.2023.115165","article-title":"Predictors of response and remission in patients with treatment-resistant depression: a post hoc pooled analysis of two acute trials of esketamine nasal spray","volume":"323","author":"Turkoz","year":"2023","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2023.09.030_bb0255","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.4088\/JCP.10m06419","article-title":"Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study","volume":"72","author":"Uher","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2023.09.030_bb0260","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m12891","article-title":"Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2)","volume":"81","author":"Wajs","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jad.2023.09.030_bb0265","series-title":"Depression [WWW Document]","author":"World Health Organization","year":"2021"},{"key":"10.1016\/j.jad.2023.09.030_bb0270","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"key":"10.1016\/j.jad.2023.09.030_bb0275","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.acra.2013.02.004","article-title":"Optimal thresholds by maximizing or minimizing various metrics via ROC-type analysis","volume":"20","author":"Zou","year":"2013","journal-title":"Acad. Radiol."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032723011680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032723011680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T23:57:20Z","timestamp":1716335840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032723011680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":55,"alternative-id":["S0165032723011680"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2023.09.030","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early effects predict trajectories of response to esketamine in treatment-resistant depression","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2023.09.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}